We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Abemaciclib plus Endocrine Therapy Offers Invasive Disease--Free Survival Benefit in Patients with High-Risk, HR-Positive, Early-Stage Breast Cancer.
- Authors
Stewart, Patricia
- Abstract
The article focuses on research which shows addition of cyclindependent kinase (CDK)4/6 inhibitor abemaciclib to standard endocrine therapy reduced the risk for invasive disease recurrence or death in patients with high-risk, hormone receptor positive, human epidermal growth receptor 2 negative breast cancer. Topics include reduction in the risk of developing invasive disease–free survival; use of abemaciclib in combination with endocrine therapy; and safety profile of abemaciclib .
- Subjects
HORMONE therapy; BREAST cancer; CANCER patients; METASTATIC breast cancer; TERMINATION of treatment
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 4, p9
- ISSN
2164-4403
- Publication type
Article